Research Keyword: glutamatergic signaling

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Read More »

Are Side Effects Necessary for Antidepressive Treatment: The Psilocybin Experience

Researchers are studying psilocybin (a compound from certain mushrooms) as a potential treatment for depression. However, there is debate about whether the hallucinogenic side effects are necessary for its therapeutic benefits. This paper argues that new research suggests the antidepressant effects work through specific brain pathways (serotonin, opioid, and glutamate systems) that don’t require hallucinations. The author suggests developing safer, non-hallucinogenic antidepressants that maintain the same therapeutic benefits.

Read More »

New and emerging pharmacologic treatments for MDD

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »
Scroll to Top